You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 126 No. 4, April 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE 43RD ANNUAL CANCER SYMPOSIUM OF THE SOCIETY OF SURGICAL ONCOLOGY, WASHINGTON, DC, MAY 19 TO 22, 1990-PAR T II
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

A Cytotoxic T-Lymphocyte Clone Derived From Mice With Progressively Growing Tumors

Shelley K. Hoover, PhD; Thomas H. Inge; James L. Frank, MD; J. Gregory McKinnon, MD; John Monaco, PhD; Brian Susskind, PhD; Harry D. Bear, MD, PhD

Arch Surg. 1991;126(4):447-452.


Abstract

• Tumor-specific T-cell clones were derived from spleen cells of mice bearing a syngeneic PHS-5 tumor (a P815 mastocytoma mutant). Cells were expanded in vitro and characterized and assayed for activity against the relevant tumor in vivo. Clone cells were CD4–, CD8+ T lymphocytes, as determined by fluorescence activated cell sorting analysis and were specifically cytotoxic against P815 tumor cells in vitro, as shown in chromium 51 release assays. These cells require both antigen and interleukin 2 to proliferate; neither alone is sufficient, even with the addition of interleukin 1. In an experimental P815 liver metastasis model, the adoptive transfer of GD11 or GD11.17 clone cells and injection of recombinant interleukin 2 (7500 U intraperitoneally) 3 days after infusion of tumor cells reduced the number of tumor nodules, while the adoptive transfer of lymphokine-activated killer cells was ineffective.

(Arch Surg. 1991;126:447-452)



Author Affiliations

From the Massey Cancer Center (Drs Hoover, Frank, Susskind, and Bear and Mr Inge) and Departments of Surgery (Drs Hoover, Frank, Susskind, and Bear) and Microbiology and Immunology (Drs Monaco, Susskind, and Bear and Mr Inge), Medical College of Virginia, Virginia Commonwealth University, Richmond; and University of Calgary, Alberta (Dr McKinnon).


Footnotes

Accepted for publication December 1, 1990.

Read before the 43rd Annual Meeting of the Society of Surgical Oncology, Washington, DC, May 20, 1990.

Reprint requests to Box 11, MCV Station, Medical College of Virginia, Richmond, VA 23298 (Dr Bear).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.